百济神州午前涨超3% 首季度业绩符合市场预期 主要产品在美市场份额持续提升

Core Viewpoint - BeiGene reported a significant revenue increase in Q1 2025, achieving 8.048 billion yuan, a year-on-year growth of 50.2%, with a notable reduction in net loss, indicating a positive trend in financial performance [1][2] Financial Performance - Q1 2025 revenue reached 8.048 billion yuan, up 50.2% year-on-year, with product revenue at 7.985 billion yuan, a 49.9% increase [1] - The net profit attributable to shareholders was -95 million yuan, a substantial improvement from -1.908 billion yuan in the same period last year [1] - According to GAAP, the company achieved its first quarterly profit, aligning with market expectations [1] Product Sales Growth - The growth in product revenue was primarily driven by self-developed product Zanubrutinib, along with sales increases of Tislelizumab and Amgen licensed products [1] - Zanubrutinib's global sales totaled 5.692 billion yuan, reflecting a 63.7% increase, with U.S. sales at 4.041 billion yuan, up 61.9% [1] - European sales of Zanubrutinib reached 836 million yuan, a 75.4% increase, while sales in China were 590 million yuan, up 43.1% [1] Future Outlook - Sales of Tislelizumab in Q1 2025 amounted to 1.245 billion yuan, marking a 19.3% increase [2] - The company maintains its full-year revenue guidance for 2025 at 4.9 to 5.3 billion USD, driven by the strong market position of Zanubrutinib in the U.S. and ongoing expansion in Europe and other key global markets [2]